Ethos Laboratories is excited to launch our Targeted Biochemical Assessment (TBA). This group of assays allows healthcare providers to target and confirm metabolic pathway disruption for improved patient outcomes. Metabolite accumulation or deficiency can confirm the presence of suspected endocrine, metabolic, and/or nutritional disorders. The TBA report provides individual results, recommendations to address abnormalities, and an assessment history to determine the results of treatment plans. For more information about Targeted Biochemical Assessment, visit www.ethos-labs.com or email [email protected].
Ethos Laboratories’ Post
More Relevant Posts
-
Pharmacogenetic testing provides a better understanding of how your patients will respond to medications by analyzing patient genotypes. With our PGx Testing, healthcare professionals can avoid trial-and-error dosing and reduce the risk of potential adverse drug events. https://lnkd.in/gzQzsAPg #genetics #diagnostics #genes #prescriptiondrugs
Pharmacogenetic (PGx) Testing
genviewdx.com
-
Regional Market Development Manager Genetic Testing Solutions chez Thermo Fisher Scientific
Yesterday, March 24th, was Adverse Drug Event (ADE) Awareness Day. Pharmacogenomics, the study of how an individual's genetic makeup affects their response to medications, plays a crucial role in reducing the risk of adverse drug events. By understanding an individual's genetic variations, healthcare professionals could tailor medication choices and dosages to optimize effectiveness while minimizing the potential for harm. On ADE Awareness Day, we aimed to shed light on the importance of pharmacogenomics in personalized medicine. Read our recent blog here. #thermofisheremp
The Need for Pharmacogenomic Testing to Prevent Adverse Drug Events
thermofisher.com
-
Technical / Marketing expertise related to Genotyping (AgBio and Human) and Gene Expression applications.
Yesterday, March 24th, was Adverse Drug Event (ADE) Awareness Day. Pharmacogenomics, the study of how an individual's genetic makeup affects their response to medications, plays a crucial role in reducing the risk of adverse drug events. By understanding an individual's genetic variations, healthcare professionals could tailor medication choices and dosages to optimize effectiveness while minimizing the potential for harm. On ADE Awareness Day, we aimed to shed light on the importance of pharmacogenomics in personalized medicine. Read our recent blog here. #thermofisheremp
The Need for Pharmacogenomic Testing to Prevent Adverse Drug Events
thermofisher.com
-
Inflammatory bowel disease (IBD) is a prevalent chronic disease with high unmet medical need. Menten AI’s platform can design new peptides with potential to improve patient care where other modalities cannot ✅ Learn more by reaching out! https://www.menten.ai/ 🧐 #peptides #generativeai #artificialgeneralintelligence #ai #biotechnology #drugdiscovery #pharmaceuticalindustry #ibdawareness #mentenai
-
-
Yesterday, March 24th, was Adverse Drug Event (ADE) Awareness Day. Pharmacogenomics, the study of how an individual's genetic makeup affects their response to medications, plays a crucial role in reducing the risk of adverse drug events. By understanding an individual's genetic variations, healthcare professionals could tailor medication choices and dosages to optimize effectiveness while minimizing the potential for harm. On ADE Awareness Day, we aimed to shed light on the importance of pharmacogenomics in personalized medicine. Read our recent blog here. #thermofisheremp
The Need for Pharmacogenomic Testing to Prevent Adverse Drug Events
thermofisher.com
-
Technical / Marketing expertise related to Genotyping (AgBio and Human) and Gene Expression applications.
Yesterday, March 24th, was Adverse Drug Event (ADE) Awareness Day. Pharmacogenomics, the study of how an individual's genetic makeup affects their response to medications, plays a crucial role in reducing the risk of adverse drug events. By understanding an individual's genetic variations, healthcare professionals could tailor medication choices and dosages to optimize effectiveness while minimizing the potential for harm. On ADE Awareness Day, we aimed to shed light on the importance of pharmacogenomics in personalized medicine. Read our recent blog here. #thermofisheremp
The Need for Pharmacogenomic Testing to Prevent Adverse Drug Events
thermofisher.com
-
𝐈𝐧𝐧𝐨𝐂𝐚𝐫𝐞 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈 𝐒𝐭𝐮𝐝𝐲 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐓𝐘𝐊𝟐 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐈𝐂𝐏-𝟑𝟑𝟐 𝐌𝐞𝐞𝐭 𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐄𝐧𝐝𝐩𝐨𝐢𝐧𝐭 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐀𝐭𝐨𝐦𝐢𝐜 𝐃𝐞𝐫𝐦𝐚𝐭𝐢𝐭𝐢𝐬 InnoCare Pharma (HKEX: 09969; SSE: 688428)InnoCare Pharma 诺诚健华(HKEX: 09969; SSE: 688428) announces positive Phase II results for TYK2 inhibitor ICP-332 in treating moderate-to-severe atopic dermatitis (AD). In a 4-week study, ICP-332 demonstrated excellent efficacy and safety, achieving primary endpoints such as EASI 50, EASI 75, EASI 90, and IGA 0/1 in the 80mg and/or 120mg dosing groups. The mean percentage change in EASI score reached 78.2% and 72.5% at 80mg and 120mg doses, significantly higher than the placebo. ICP-332 exhibited good tolerability, with mild or moderate treatment-related adverse events. Dr. Jasmine Cui, CEO of InnoCare, emphasizes the potential impact on patients with AD and other autoimmune diseases. Currently, no globally approved TYK2 inhibitor for AD exists, and the market potential is estimated at $10 billion by 2030. ICP-332, a selective TYK-2 inhibitor, shows promise in addressing unmet medical needs in AD and inflammatory diseases. #inflammatory #healthcare #treatment #disease #medical #autoimmnue #patient #china
-
